Few predictive factors for symptomatic progression of gallstone disease:
- Bariatric surgery - 30% develop gallstones
- post-colectomy - 20% will develop symptoms within 5 years
- prolonged TPN use
Despite these risk factors, there are few indications for prophylactic cholecystectomy:
- Expectant Management of Cholelithiasis is the accepted treatment despite low morbidity of lap chole
- Diabetes is not an indication for prophylactic chole. Diabetics do not have any significant difference in prevalence, presentation or complications compared to nondiabetics
Post-Transplantation:
- Cyclosporine leads to gallstone formation.
- Need for prophylactic chole has been shown to be of benefit in cardiac transplant patients if screening u/s shows stones (Milas et al, Mayo clinic)
- in renal transplant patients, majority (~90%) remain asymptomatic
Hemoglobinopathies:
- at risk of developing pigmented stones.
- sickle cell: 70% of pts
- hereditary spherocytosis: 85%
- thalassemia: 24%
- Gallstones in sickle cell patients can pose a problem. ~50% will become symptomatic within 3-5 years. Presence of gallstones can be diagnostically challenging due to possibility of abdominal sickling crisis.
- Hemoglobinopathies are an indication to perform prophylactic lap chole, lap chole should also be performed if doing a lap splenectomy
Bariatric Surgery:
- incidence of gallstone formation after rapid weight loss:
- general population: 10-20%
- bariatric surgery population: 30-40%
- if gallstones documented at time of bariatric surgery - lap chole recommended
- Ursodiol - can decrease incidence if patient compliant (prevents cholesterol absorption, expensive (~$1.50/d), BID). Suggested for patients undergoing bariatric surgery without prior evidence of stones.
Incidental Cholecystectomy - Controversial:
- During AAA: controversial due to the presence of graft material. Review of incidental chole - shown to be safe as long as performed after retroperitoneum is closed
- Other abdominal surgeries: One study (Watemberg et al) showed that in pts >70 yo with cholelithiasis, M&M was higher if you DO NOT do incidental chole during laparotomy for other reasons.... yet we do not routinely do this in practice - why?
- most were small studies - only Watemberg was larger study
Thursday, January 21, 2010
Wednesday, January 20, 2010
CBD injuries
Strasberg classification CBD injuries
Sent from iPhone
Sent from iPhone
Tuesday, January 19, 2010
Gallbladder Polyps
Prevalence GB Polyps: 3-10%
Differential:
- Cholesterol polyps (50-70%)
- inflammatory
- hyperplastic
- adenoma
- malignant (8%)
Predictive factors for malignancy:
- size >1cm
- broad based sessile polyps
- age >50
Treatment:
- suspicion for GB cancer low: lap chole
- suspicious for GB cancer: open chole with intraop frozen section
- small polypoid lesion: U/S q6 mo for 2 yrs to ensure stable lesion
Differential:
- Cholesterol polyps (50-70%)
- inflammatory
- hyperplastic
- adenoma
- malignant (8%)
Predictive factors for malignancy:
- size >1cm
- broad based sessile polyps
- age >50
Treatment:
- suspicion for GB cancer low: lap chole
- suspicious for GB cancer: open chole with intraop frozen section
- small polypoid lesion: U/S q6 mo for 2 yrs to ensure stable lesion
Gallbladder Cancer
T1a GB Ca: usually early stage
- usually found incidentally after routine lap chole
- incidence after routine lap chole for cholelithiasis - 1-2%
- 5 year survival for T1a GB ca confined to the mucosa - 85-100%Symptomatic patients: usually advanced stage
- U/S only 50% sensitive for GB ca
- if suspicion of GB cancer pt should have a CT scan or MRI to look for invasion into adjacent structures, LN or encasement of portal vein or hepatic artery.
- Other investigations to consider: PET, MRCP, ERCP
Treatment is based T-stage of the tumor
- contraindications to surgical resection: liver mets, malignant ascites, peritoneal mets, distant disease, extensive involvement of hepatoduodenal ligament, encasement or occlusion of major vessels, poor performance status.
Lap Chole:
Tis or T1a
Radical Cholecystectomy:
-T1b (15% subserosal LN involvement) or T2 (40-80% subserosal LN involvement)
- radical cholecystectomy involves resection of GB with a 2cm hepatic parenchymal margin and LN dissection within the porta hepatis, gastroduodenal ligament, gastrohepatic ligament and Kocher for LN dissection behind duodenum
- can be done at time of initial lap chole or can be delayed - survival the same
- can be done at time of initial lap chole or can be delayed - survival the same
Radical Cholecystectomy +/- en bloc resection of locally invaded organs:
- advised for T3/T4 tumors only if there is no evidence of metastatic spread
- 25-44% 5 year survival rate
Palliation:
- survival in locally unresectable or metastative disease often <1 yr
- no effective adjuvant treatment - all part of clinical trials
Palliation:
- survival in locally unresectable or metastative disease often <1 yr
- no effective adjuvant treatment - all part of clinical trials
Friday, January 15, 2010
Hepatocellular Carcinoma
Hep C is highest risk factor worldwide of HCC (>50% in NA)
- any type of cirrhosis carries risk of HCC
- what about Hep A (or is it only chronic Hepatides)
Screening in cirrhotic pts important:
- clinical presentation will be late in disease process
- AFP, U/S q6 months
- any solid liver nodule not clearly a hemangioma should be considered an HCC in a cirrhotic pt until proven otherwise
REsection
Child PUgh A - normal bili, INR, albumin, no encephalopathy, no ascites
unilobar
no major co-morbidites
Malignant liver tumors
American Associatiion of Liver Disease HCC diagnostic criteria
- ?
- main point is that FNA not necessarily required for diagnosis and may track tumor in needle site converting treatable lesion to untreatable
Treatments for HCC
Curative:
- TRansplant
- resection
- Radiofrequency ablation
Palliative
- TASTE (embolization)
- chemotherapy
Best treatment modality HCC:
- Transplant (treats both tumor underlying liver dysfunction)
- resection has 50% 5 year survival (largely from liver disease and risk of 2nd primary)
Factors for HCC resection
- liver function
- tumor characteristics (number, size, multifocality)
Primary liver tumors:
HCC
cholangiocarcinoma
malignant vascular tumors (epitheliod hemangioendothelioma, angiosarcoma)
sarcomas (embryonal sarcoma, ...)
Most common sources of liver mets (hypoattenuating):
Colorectal, Breast, Lung
Hyperattenuating:
- melanoma, renal cell
Treatment goals:
- R0 resection
- preserve ~25% hepatic parenchyma
- adjuvant or neoadjuvant chemoRT to reduce risk recurrence
Benign liver lesions - AHD
3 most common benign liver lesions:
1) Adenoma
2) FNH
3) hemangioma
Factors for resection:
- symptoms (chronic, aching pain under the right costal margin, constant)
- type (adenomas carry malignancy risk, FNH do not)
- location (peripheral hemangioma at risk of rupture)
- growth (compression of biliary/vascular strucutres)
Subscribe to:
Posts (Atom)